Page 4 - reflections_dyslipidaemia_newsletter7_2024
P. 4
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #7 2024
Dyslipidaemia
The authors suggest a multipronged approach to lowering
ASCVD events, including addressing modifiable risk factors CLINICAL PEARLS FROM THE FACULTY
through diet, exercise, and smoking cession; increasing patient
adherence to lipid-lowering therapy; and increasing access to
lipid-lowering therapy.
The authors conclude that starting combination lipid-lowering
therapy in high-risk patients at diagnosis will reduce treatment
delays and allow for larger reductions in LDL-C in a shorter time
frame, such as four to five weeks. They implore clinicians to
incorporate upfront or early combination lipid-lowering therapy in
the management of select high-risk patients.
WATCH
DR. WELNICKI DISCUSS THE
CLICK HERE RELEVANCE OF THIS ARTICLE FOR
FOR THE LINK TO FULL ARTICLE CLINICAL PRACTICE.
TABLE OF CONTENTS
